KNP 701
Alternative Names: KNP-701Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Kanaph Therapeutics
- Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-small cell lung cancer; Solid tumours
Most Recent Events
- 10 Sep 2024 Early research in Non-small cell lung cancer in South Korea (Parenteral), before September 2024 (Kanaph Therapeutics pipeline, September 2024
- 10 Sep 2024 Early research in Solid tumours in South Korea (Parenteral), before September 2024 (Kanaph Therapeutics pipeline, September 2024)